Published in Drugs on March 26, 2010
Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity (2012) 3.49
Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity (2010) 1.70
The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol (2012) 1.49
APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. Arthritis Res Ther (2012) 1.00
Basophils and autoreactive IgE in the pathogenesis of systemic lupus erythematosus. Curr Allergy Asthma Rep (2011) 0.89
Clearing the complexity: immune complexes and their treatment in lupus nephritis. Int J Nephrol Renovasc Dis (2011) 0.79
Expression of toll-like receptors 3, 7, and 9 in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Mediators Inflamm (2014) 0.79
Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus. PLoS One (2014) 0.79
Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature. Lupus (2013) 0.77
Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice. Acta Pharmacol Sin (2015) 0.75
Decrease of functional activated T and B cells and treatment of glomerulonephitis in lupus-prone mice using a natural flavonoid astilbin. PLoS One (2015) 0.75
Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis. JCI Insight (2017) 0.75
Blockade of co-stimulation in chronic inflammatory diseases. Wien Med Wochenschr (2014) 0.75